NEW YORK (GenomeWeb) – Guardant Health and Principia Biopharma plan to collaborate on clinical trials for cancer therapies, the firms said today.
The pharmaceutical company will use Guardant Health's circulating tumor DNA assay, Guardant360, to monitor patients enrolled in a clinical trial for Principia's FGFR inhibitor, PRN1371, which is being developed for multiple indications.
The companies will use the Guardant360 assay, which assesses 70 genes from cell-free DNA to genomically profile patients' tumors and assess how they change in response to the drug.
The assay "gives us an opportunity to track tumor genetic alterations over time, and to evaluate the effects of Principia’s highly targeted FGFR therapy in our phase 1 clinical trial," Principia CEO Martin Babler said in a statement.
The collaboration with Principia is the second collaboration with a pharmaceutical company that Guardant has publicly announced. Last December, it said it would collaborate with Mirati Therapeutics to use its assay to screen lung cancer patients eligible for a phase 2 clinical trial of glesatinib, and that the collaboration could potentially result in a regulatory submission of Guardant360 as a companion diagnostic.